Neoplasms

Blood and Lymph Conditions

All Conditions

Hematologic Neoplasms

Hematologic Diseases

Antineoplastic Agents

All Drugs and Chemicals

Fludarabine

Fludarabine phosphate

Busulfan

Alkylating Agents

Immunosuppressive Agents

Immunologic Factors

Antineoplastic Agents, Alkylating

intravenous busulfan

Rachel Syme, PhD

Chris Brown

Ron Anderson

James Russell

Victor Lewis

James Russell, FRCp

A study of pharmacokinetics of daily intravenous busulfan

Busulfan and Fludarabine as Conditioning for Allogeneic Stem Cell Transplantation: a Pharmacokinetic Study

Busulfan and Fludarabine as Conditioning for Allogeneic Stem Cell

Alberta Health services

Heart and Blood Diseases

Immune System Diseases

Rare Diseases

Multiple Myeloma

Neoplasms, Plasma Cell

Neoplasms by Histologic Type

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

Melphalan

BU is administered intravenously at a dose of 3.2 mg/kg over three hours once a day on days -5 to -3 (total dose 9.6 mg/kg), followed by MEL at a dose of 140 mg/m2 on day -2. After one day of rest, progenitor cells are infused on day 0.

Intravenous busulfan and melphalan

Javier de la Rubia, MD

Guillermo Sanz, MD

Juan D González, MD

Adrián Alegre, MD

Juan J Lahuerta, MD

Isidro Jarque, MD

Carlos Solano, MD

Paz Ribas, MD

Miguel A Sanz, MD

Analyze the results of ASCT using intravenous Busulfan and Melphalan as conditioning regimen for patients with Multiple Myeloma.

Primary Efficacy and safety of the procedure in terms of number of remissions, survival, event-free survival, relapse risk, and early transplant-related mortality (up to day +100).

Secondary Graft kinetics (time to neutrophil and platelet recovery after ASCT) 2.Analyze the presence of transplant-related complications (infections, sinusoidal occlusive syndrome and others) 3.Analyze prognostic factors for engraftment, remission rate, relapse risk, disease-free and overall survival after ASCT

Autologous Stem Cell Transplant (ASCT) With Intravenous Busulfan and Melphalan as Conditioning Regimen

Ensayo Fase II de Trasplante autólogo de Sangre periférica en Pacientes Con Mieloma múltiple Tras Acondicionamiento Con Busulfan Intravenoso y Melfalan

Fundacion Para La Investigacion Hospital La Fe

Javier de la Rubia

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Busulfan and Fludarabine as Conditioning for Allogeneic Stem Cell Transplantation: a Pharmacokinetic Study	NCT00156858	Hematologic Mal...	intravenous bus...	- 70 Years	AHS Cancer Control Alberta
Autologous Stem Cell Transplant (ASCT) With Intravenous Busulfan and Melphalan as Conditioning Regimen	NCT00804947	Multiple Myelom...	Intravenous bus...	18 Years - 70 Years	Fundacion Para La Investigacion Hospital La Fe

Spots Global Cancer Trial Database for intravenous busulfan